A systematic method for selection of promising serum protein biomarkers to improve prostate cancer (PCa1) detection.
Invitrogen Corporation, 5781 Van Allen Way, Carlsbad, CA 92008, USA. judith.finlay@invitrogen.com
Judith A
JA
Finlay
Eric W
EW
Klee
Cari
C
McDonald
John R
JR
Attewell
Deanne
D
Hebrink
Roy
R
Dyer
Brad
B
Love
George
G
Vasmatzis
Thomas M
TM
Li
Joseph M
JM
Beechem
George G
GG
Klee
D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis*; D019295:Computational Biology; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D011933:Reagent Kits, Diagnostic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D044967:Serum
D014408:Biomarkers, Tumor; D001798:Blood Proteins; D011933:Reagent Kits, Diagnostic; D017430:Prostate-Specific Antigen